Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies,
are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC …

Liver cancer is the second leading cause of cancer mortality worldwide, causing more than
700,000 deaths annually. Because of the wide landscape of genomic alterations and limited …

Hepatocellular carcinoma (HCC) is one of the most aggressive types of cancer and lacks
effective therapeutic approaches. Most HCC develops in the setting of chronic liver injury …

Introduction: Non-invasive assessment of fibrosis is increasingly utilized in clinical practice
to diagnose hepatic fibrosis. Non-invasive assessment of liver fibrosis relies on biologic …

Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a
consequence of failed early detection. Professional societies recommend semi‐annual HCC …

Chronic liver injury due to viral hepatitis, alcohol abuse, and metabolic disorders is a
worldwide health concern. Insufficient treatment of chronic liver injury leads to fibrosis …

The extracellular matrix (ECM) is a significant factor in cancer progression. Collagens, as the
main component of the ECM, are greatly remodeled alongside cancer development. More …

This review evaluates the ability of the fibrosis index based on four factors (FIB-4) identifying
fibrosis stages, long-time prognosis in chronic liver disease, and short-time outcomes in …

Chronic hepatitis B virus (HBV) infection is a major cause of liver morbidity and mortality
worldwide. While a proportion of the 250 million individuals chronically infected with HBV …

Immune checkpoint blockade is considered a breakthrough in cancer treatment. However,
with the low response rates and therapeutic resistance of patients with hepatocellular …